Results 11 to 20 of about 205,880 (261)
World Journal of Microbiology & Biotechnology, 2022 Amikacin is an aminoglycoside antibiotic used in drug-resistant bacterial infections. The spread of bacterial infections has become a severe concern for the treatment system because of the simultaneous drug resistance bacteria and SARS-CoV-2 hospitalized
M. Rahmati +2 more
semanticscholar +1 more source
Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa
Antibiotics, 2021 Pseudomonas aeruginosa is an opportunistic nosocomial pathogen associated with high morbidity and mortality rates. Combination of antibiotics has been found to combat multi-drug resistant or extensively drug resistance P. aeruginosa.
Sara Mahmoud Farhan +6 more
doaj +1 more source
European journal of pharmaceutics and biopharmaceutics, 2021 The purpose of these studies was to understand the effect on product performance of batch-to-batch variability in both the amikacin liposome inhalation suspension (ALIS) formulation and its delivery device, the Lamira® nebulizer system, designed and ...
Zhili Li, W. Perkins, D. Cipolla
semanticscholar +1 more source
Review on Population Pharmacokinetics of Amikacin in Paediatrics
Journal of Pure and Applied Microbiology, 2022 Amikacin is an aminoglycoside antibiotic with a broad-spectrum bacterial coverage that is frequently utilized both as monotherapy and in combination with other antibiotics for severe bacterial infections in the paediatric population.
Keerthana Chandrasekar +4 more
doaj +1 more source
Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
Scientific Reports, 2021 Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss.
Kuan-Jen Chen +10 more
semanticscholar +1 more source
The role of amikacin in the treatment of nontuberculous mycobacterial disease
Expert Opinion on Pharmacotherapy, 2021 Introduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.
J. Raaijmakers +3 more
semanticscholar +1 more source
Frontiers in Microbiology, 2022 Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and sulbactam are co-administered, the combinations exhibit in vitro synergistic ...
Shixing Zhu +11 more
doaj +1 more source
European journal of drug metabolism and pharmacokinetics, 2021 Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic ...
C. Rubino +7 more
semanticscholar +1 more source
Antibiotics, 2022 For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management ...
Manas S. Deolankar +5 more
doaj +1 more source
Microorganisms, 2023 Mycobacterium abscessus complex infections are ever on the rise. To curb their increasing evolution, we performed an in-depth study of 43 clinical isolates of cystic fibrosis patients obtained from 2009 to 2020.
Juan Carlos Cao Yao +2 more
doaj +1 more source